These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8611053)

  • 1. [Early clinical trials in ECTG. Early Clinical Trial Group].
    Ogawa M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):238-41. PubMed ID: 8611053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phased clinical trials in cancer chemotherapy].
    Yokoyama M
    Gan No Rinsho; 1983 Aug; 29(10):1205-16. PubMed ID: 6355555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and benefits associated with novel phase 1 oncology trial designs.
    Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
    Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneously optimizing dose and schedule of a new cytotoxic agent.
    Braun TM; Thall PF; Nguyen H; de Lima M
    Clin Trials; 2007; 4(2):113-24. PubMed ID: 17456511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient specific dosing in a cancer phase I clinical trial.
    Babb JS; Rogatko A
    Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies.
    Newell DR; Silvester J; McDowell C; Burtles SS;
    Eur J Cancer; 2004 Apr; 40(6):899-906. PubMed ID: 15120045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Accelerated titration design].
    Minami H
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Introduction of anticancer agents to phase I clinical trials].
    Shimoyama M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.